Skip to main contentSkip to navigation
Sirius Investors

CRXTQ Stock: Clarus Therapeutics Holdings, Inc. Stock Price, Analysis & Insights

Get live CRXTQ stock price $0.00, comprehensive Clarus Therapeutics Holdings, Inc. stock analysis, charts, news, and expert forecast. Real-time CRXTQ stock data and investment insights.

0.00
0.00%Today
CRXTQClarus Therapeutics Holdings, Inc. • Other OTC • Healthcare
Market Cap
72.83K
Volume
38.26K
52W High
3.94
52W Low
0.00

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone un...

Company Information

CEO
Robert E. Dudley
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
16

Contact Information

Address
555 Skokie Boulevard
Country
US

Investment Analysis & Business Insights

Healthcare
Drug Manufacturers - General

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 1.68)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Clarus Therapeutics Holdings, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Clarus Therapeutics Holdings, Inc.
  • Investors should consider how Clarus Therapeutics Holdings, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

72.83K

P/E Ratio (TTM)

-0.00

Beta

1.68

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.